Patent ID: 8921528
Filing Date: 2014-12-30
Classification: A61K,A61P,C07K

Abstract:
1. A drug fusion comprising moieties X′ and Y′, wherein X′ is a polypeptide drug, with the proviso that X′ does not comprise an antibody chain or a fragment of an antibody chain; and Y′ is an immunoglobulin single variable domain that has binding specificity for serum albumin, wherein Y′ is an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23; and wherein said drug fusion has a longer in vivo serum half-life relative to said polypeptide drug.